首页> BMC cancer> Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.

导出 OA

翻译打印收藏纠错

第一作者： Chris,Twelves

第一单位： Clinical Cancer Pharmacology and Oncology, Leeds Cancer Centre, St James's University Hospital, Level 4, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK. c.j.twelves@leeds.ac.uk.;University of Leeds, Leeds, UK. c.j.twelves@leeds.ac.uk.

作者： Chris,Twelves ^[1] ; Sue,Cheeseman ^[2] ; Will,Sopwith ^[3] ; Matthew,Thompson ^[2] ; Majid,Riaz ^[2] ; Necibe,Ahat-Donker ^[3] ; Melissa,Myland ^[4] ; Adam,Lee ^[5] ; Raymond,Przybysz ^[6] ; Stuart,Turner ^[6] ; Geoff,Hall ^[7] ; Tim,Perren ^[7]

作者单位： Clinical Cancer Pharmacology and Oncology, Leeds Cancer Centre, St James's University Hospital, Level 4, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK. c.j.twelves@leeds.ac.uk.;University of Leeds, Leeds, UK. c.j.twelves@leeds.ac.uk. ^[1] Clinical Cancer Pharmacology and Oncology, Leeds Cancer Centre, St James's University Hospital, Level 4, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK. ^[2] Clinical Cancer Pharmacology and Oncology, Leeds Cancer Centre, St James's University Hospital, Level 4, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK.;IQVIA, London, UK. ^[3] IQVIA, London, UK. ^[4] Novartis Pharmaceuticals UK Ltd, Surrey, UK. ^[5] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. ^[6] Clinical Cancer Pharmacology and Oncology, Leeds Cancer Centre, St James's University Hospital, Level 4, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK.;University of Leeds, Leeds, UK. ^[7]

关键词 Chemotherapy Endocrine therapy HR+/HER2-Metastatic breast cancer Overall survival